Shares of Injecto Polymers and Century Business Media are set to make their debut on the BSE SME platform On September 21, marking the listing of two recently concluded SME public issues.
Among the two offerings, the Century Business Media IPO received an overwhelming response from investors, with the issue subscribed 57.93 times by the close of bidding. The Injecto Polymers IPO, meanwhile, was subscribed 1.23 times.
Injecto Polymers raised Rs 56.12 crore through its book-built issue, while Century Business Media raised Rs 17.11 crore. Both IPOs comprised entirely fresh issues of shares.
Read more: NSE IPO Tracker: Catch all the highlights here
The Century Business Media IPO raised Rs 17.11 crore through a book-built issue, comprising a fresh issue of 23.12 lakh shares.
The issue was subscribed 57.93 times overall. The portion reserved for individual investors was subscribed 39.81 times, while the QIB (Ex-Anchor) category was subscribed 47.53 times. The NII category witnessed the strongest demand, with subscription reaching 113.88 times.
The company fixed the IPO price band at Rs 70–Rs 74 per share, with a lot size of 1,600 shares. At the upper end of the price band, the minimum retail application required 3,200 shares, translating into an investment of Rs 2.36 lakh.
The IPO opened for subscription on September 11, 2026, and closed on September 16, 2026. The allotment was finalised on September 17, while the shares are scheduled to debut on the BSE SME platform on September 21, 2026.
Read more: Three SME IPOs open for subscription today: Check price band, lot size and key details
Hem Securities Ltd. is the book-running lead manager for the issue, while KFin Technologies Ltd. is the registrar.
IPO proceeds: Century Business Media plans to use the proceeds to expand its media and advertising assets. The company proposed spending approximately Rs 4.21 crore on acquiring media assets and another Rs 3.77 crore as a security deposit for advertising rights at Patna Airport. Around Rs 3.25 crore is proposed to be allocated towards working capital requirements, while approximately Rs 1.45 crore will be used to repay certain borrowings. The remaining funds will be utilised for general corporate purposes. The total estimated utilisation of the issue proceeds for these identified purposes stands at Rs 12.68 crore.
The Injecto Polymers IPO was a Rs 56.12 crore book-built issue comprising an entirely fresh issue of 56.12 lakh shares.
The IPO opened for subscription on September 11, 2026, and closed on September 16, 2026. The issue was subscribed 1.23 times overall.
The individual investor category was subscribed 1.28 times, while the QIB (Ex-Anchor) portion received 1.57 times subscription. The NII category was subscribed 1.05 times.
Injecto Polymers fixed the IPO price band at Rs 98–Rs 100 per share, with a lot size of 1,200 shares. At the upper end of the price band, a retail investor applying for the minimum retail requirement of 2,400 shares would need to invest Rs 2.40 lakh.
The company is scheduled to make its debut on the BSE SME platform on September 21, 2026.
Read more: Manika Plastech shares to list today; check GMP ahead of debut
Indcap Advisors Pvt. Ltd. is the book-running lead manager, while Integrated Registry Management Services Pvt. Ltd. is the registrar to the issue.
IPO proceeds: Injecto Polymers plans to deploy a significant portion of the IPO proceeds towards debt reduction and expansion of its manufacturing capacity. Around Rs 10 crore is proposed to be used for the repayment or pre-payment, either fully or partially, of certain outstanding borrowings. Another Rs 30.50 crore has been earmarked for capital expenditure related to the proposed Phase IV expansion at the company's existing manufacturing facility, Unit-I, located on NH2 Bypass Road, Jaugram, Abujhati, Jamalpur, West Bengal. The remaining proceeds will be utilised for general corporate purposes. The total estimated utilisation of the issue proceeds for the specified purposes stands at Rs 40.50 crore.
Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
